Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Quest Diagnostics Incorporated DGX

Healthcare  —  Diagnostics & Research
236.32 (0.27) (0.11%) as of 25 Sep
Market cap
$26.2B
P/E
24.8×
S&P 500 Member Dividend Champion (5y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Quest Diagnostics Incorporated (DGX) Business Profile

Updated before January 2025

Company Overview

Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic information services, headquartered in Secaucus, New Jersey, USA. The company was founded in 1967 as Metropolitan Pathology Laboratory, Inc., and later rebranded as Quest Diagnostics in 1996. Over the years, Quest Diagnostics has grown into one of the largest diagnostic testing companies in the world, serving millions of patients annually. The company operates a vast network of laboratories and patient service centers across the United States and internationally.

Key leadership includes James E. Davis, who serves as the Chief Executive Officer (CEO). Under his leadership, Quest Diagnostics has focused on innovation, operational efficiency, and expanding its portfolio of diagnostic services to meet the evolving needs of healthcare providers and patients.

Core Business Segments

Quest Diagnostics operates through several core business segments, offering a wide range of diagnostic testing services and solutions. These include:

1. Diagnostic Information Services (DIS)

This is the primary revenue-generating segment for Quest Diagnostics. It includes:

  • Routine Testing: Blood tests, urine tests, and other routine diagnostic services for general health assessments.
  • Advanced Diagnostics: Specialized testing services such as genetic testing, oncology diagnostics, and infectious disease testing.
  • Wellness and Preventive Testing: Services aimed at early detection and prevention of diseases, including health risk assessments and biometric screenings.

2. Employer Solutions

Quest Diagnostics provides drug testing and wellness programs for employers. These services include:

  • Drug Screening: Pre-employment and random drug testing for workplace compliance.
  • Health and Wellness Programs: Biometric screenings, flu vaccinations, and health coaching services for employees.

3. Healthcare IT Solutions

Quest Diagnostics offers digital solutions to streamline healthcare processes. Key offerings include:

  • Quanum Solutions: A suite of healthcare IT tools, including electronic health records (EHR), revenue cycle management, and data analytics.
  • Connectivity Solutions: Tools that enable seamless integration between healthcare providers, payers, and patients.

4. Clinical Trials Testing

Quest Diagnostics supports pharmaceutical and biotechnology companies by providing laboratory testing services for clinical trials. This includes:

  • Specimen Collection and Analysis: Comprehensive testing services to support drug development and regulatory submissions.
  • Companion Diagnostics: Development of diagnostic tests that accompany specific therapies.

Business Model

Quest Diagnostics operates on a business-to-business (B2B) and business-to-consumer (B2C) model. The company generates revenue through:

  • Diagnostic Testing Services: Fees charged to healthcare providers, patients, and payers for laboratory testing services.
  • Partnerships and Collaborations: Collaborations with hospitals, health systems, and pharmaceutical companies to provide diagnostic services and clinical trial support.
  • Direct-to-Consumer Offerings: Online platforms that allow patients to order tests directly and access results without a physician’s referral.

The company’s integrated approach combines advanced diagnostic testing, healthcare IT solutions, and clinical trial services to deliver comprehensive healthcare solutions.

Strategic Direction

Quest Diagnostics has outlined several strategic priorities to drive future growth:

1. Expanding Diagnostic Services

The company aims to broaden its portfolio of diagnostic tests, particularly in areas such as oncology, genetics, and infectious diseases. Investments in research and development (R&D) are focused on developing innovative testing solutions.

2. Enhancing Digital Capabilities

Quest Diagnostics is investing in digital health solutions to improve patient access and streamline healthcare delivery. This includes expanding its online test ordering platform and enhancing data analytics capabilities.

3. Sustainability Goals

The company is committed to reducing its environmental footprint by adopting sustainable practices in its operations. This includes energy-efficient laboratory processes and waste reduction initiatives.

4. Geographic Expansion

Quest Diagnostics is exploring opportunities to expand its presence in international markets, particularly in regions with growing demand for diagnostic services.

Competitive Landscape

Quest Diagnostics operates in a highly competitive industry, facing competition from:

  • Laboratory Corporation of America Holdings (LabCorp): A major competitor offering similar diagnostic testing services.
  • BioReference Laboratories: A subsidiary of OPKO Health, specializing in clinical diagnostics.
  • Mayo Clinic Laboratories: Known for its specialized testing services.
  • Regional and Local Laboratories: Smaller laboratories that compete on price and localized services.
  • Emerging Digital Health Companies: Startups offering at-home testing kits and telehealth services.

Risk Factors

Quest Diagnostics faces several risks that could impact its operations and financial performance:

  • Regulatory Changes: Changes in healthcare regulations and reimbursement policies could affect revenue.
  • Market Dependence: Heavy reliance on diagnostic testing services makes the company vulnerable to market fluctuations.
  • Supply Chain Disruptions: Dependence on third-party suppliers for laboratory equipment and reagents poses a risk.
  • Competition: Intense competition from established players and new entrants could pressure pricing and market share.
  • Data Security: As a healthcare IT provider, Quest Diagnostics is exposed to cybersecurity risks and data breaches.

Recent Developments

1. COVID-19 Testing

Quest Diagnostics played a significant role in the COVID-19 pandemic by offering PCR and antibody testing services. The company rapidly scaled its testing capacity to meet unprecedented demand.

2. Acquisitions and Partnerships

Recent acquisitions, such as the purchase of select assets from Memorial Hermann Health System, have strengthened Quest Diagnostics’ presence in key markets. Partnerships with health systems and pharmaceutical companies continue to drive growth.

3. Digital Health Initiatives

The company has launched new digital tools to enhance patient engagement, including an improved online portal for test ordering and results access.

Investment Considerations

Strengths

  • Market Leadership: Quest Diagnostics is a recognized leader in the diagnostic testing industry.
  • Diverse Portfolio: A broad range of testing services and healthcare IT solutions.
  • Strong Financial Performance: Consistent revenue growth and profitability.
  • Innovation: Focus on R&D and digital health initiatives.

Risks

  • Regulatory Uncertainty: Potential changes in healthcare policies and reimbursement rates.
  • Competition: Intense competition from established players and new entrants.
  • Economic Sensitivity: Demand for diagnostic testing can be influenced by economic conditions.

Conclusion

Quest Diagnostics Incorporated is a market leader in the diagnostic testing industry, offering a comprehensive range of services and solutions. The company’s focus on innovation, digital health, and strategic partnerships positions it well for future growth. While it faces challenges such as regulatory risks and competition, its strong market presence and commitment to sustainability make it a compelling choice for investors and healthcare providers alike.